Business Today

Drug Wars

India is importing less pharmaceutical raw materials from China, but the Chinese challenge is far from over.

On January 29, 2016, the Narendra Modi government decided to withdraw the customs duty exemption on import of 73 bulk drugs. It was a tough call as import of these low cost key active pharmaceutical ingredients (APIs), or raw materials almost entirely from China was helping Indian formulation companies, or entities that make syrups, tablets, injections, etc, remain competitive. An increase in medicine prices due to rise in input costs would have been unpopular as imports included raw materials used to make life saving medicines for critical illnesses such as cancer and HIV/AIDS.

But the government bit the bullet because of a bigger threat. The import of low

You’re reading a preview, subscribe to read more.

More from Business Today

Business Today2 min read
“Hire For Attitude, Not Ability”
Thryve Digital is a player in the healthcare technology sector delivering next-generation solutions What was the problem you were grappling with? When I decided to take on the challenge of setting up Thryve Digital, there wasn’t any industry referenc
Business Today2 min read
Business Today
Chairman & Editor-in-Chief: Aroon Purie Vice Chairperson & Executive Editor-in-Chief: Kalli Purie Group Chief Executive Officer: Dinesh Bhatia Executive Director: Rahul Kanwal Chief Operating Officer: Alok Nair Editor: Sourav Majumdar Group Creative
Business Today1 min read
In Depth Knowledge From The Most Credible Source
Subscribe and get upto 72% discount

Related Books & Audiobooks